2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SNX9 determines the surface levels of integrin β1 in vascular endothelial cells: Implication in poor prognosis of human colorectal cancers overexpressing SNX9

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Angiogenesis, the formation of new blood vessels, is involved in a variety of diseases including the tumor growth. In response to various angiogenic stimulations, a number of proteins on the surface of vascular endothelial cells are activated to coordinate cell proliferation, migration, and spreading processes to form new blood vessels. Plasma membrane localization of these angiogenic proteins, which include vascular endothelial growth factor receptors and integrins, are warranted by intracellular membrane trafficking. Here, by using a siRNA library, we screened for the sorting nexin family that regulates intracellular trafficking and identified sorting nexin 9 (SNX9) as a novel angiogenic factor in human umbilical vein endothelial cells (HUVECs). SNX9 was essential for cell spreading on the Matrigel, and tube formation that mimics in vivo angiogenesis in HUVECs. SNX9 depletion significantly delayed the recycling of integrin β1, an essential adhesion molecule for angiogenesis, and reduced the surface levels of integrin β1 in HUVECs. Clinically, we showed that SNX9 protein was highly expressed in tumor endothelial cells of human colorectal cancer tissues. High‐level expression of SNX9 messenger RNA significantly correlated with poor prognosis of the patients with colorectal cancer. These results suggest that SNX9 is an angiogenic factor and provide a novel target for the development of new antiangiogenic drugs.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

          To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC). Patients with MCRC were randomly assigned, in a 2 x 2 factorial design, to XELOX versus FOLFOX-4, and then to bevacizumab versus placebo. The primary end point was progression-free survival (PFS). A total of 1,401 patients were randomly assigned in this 2 x 2 analysis. Median progression-free survival (PFS) was 9.4 months in the bevacizumab group and 8.0 months in the placebo group (hazard ratio [HR], 0.83; 97.5% CI, 0.72 to 0.95; P = .0023). Median overall survival was 21.3 months in the bevacizumab group and 19.9 months in the placebo group (HR, 0.89; 97.5% CI, 0.76 to 1.03; P = .077). Response rates were similar in both arms. Analysis of treatment withdrawals showed that, despite protocol allowance of treatment continuation until disease progression, only 29% and 47% of bevacizumab and placebo recipients, respectively, were treated until progression. The toxicity profile of bevacizumab was consistent with that documented in previous trials. The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC. Overall survival differences did not reach statistical significance, and response rate was not improved by the addition of bevacizumab. Treatment continuation until disease progression may be necessary in order to optimize the contribution of bevacizumab to therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

            Staging inadequately predicts metastatic risk in patients with colon cancer. We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence. This phase 1, exploratory biomarker study used 55 patients with colorectal cancer from Vanderbilt Medical Center (VMC) as the training dataset and 177 patients from the Moffitt Cancer Center as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A metastasis score derived from the biologically based classifier was tested in the Moffitt dataset. A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients. The metastasis score was shown to independently predict risk of cancer recurrence and death in univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566-14.05). Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time. A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.

              Primary tumor location is emerging as an important prognostic factor owing to distinct biological features. However, the side of origin of colon cancer (CC) still does not represent a prognostic parameter when deciding for adjuvant or palliative chemotherapy.
                Bookmark

                Author and article information

                Contributors
                masashim@m.ehime-u.ac.jp
                shigeki@m.ehime-u.ac.jp
                Journal
                J Cell Physiol
                J. Cell. Physiol
                10.1002/(ISSN)1097-4652
                JCP
                Journal of Cellular Physiology
                John Wiley and Sons Inc. (Hoboken )
                0021-9541
                1097-4652
                19 February 2019
                October 2019
                : 234
                : 10 ( doiID: 10.1002/jcp.v234.10 )
                : 17280-17294
                Affiliations
                [ 1 ] Department of Gastrointestinal Surgery and Surgical Oncology Ehime University Graduate School of Medicine
                [ 2 ] Department of Biochemistry and Molecular Genetics Ehime University Graduate School of Medicine Ehime Japan
                [ 3 ] Division of Cell Growth and Tumor Regulation Proteo‐Science Center, Ehime University
                [ 4 ] Division of Analytical Bio‐medicine Advanced Research Support Center, Ehime University
                [ 5 ] Department of Life Science and Medical Bioscience School of Advanced Science and Engineering, Waseda University
                [ 6 ] Department of Molecular Pathology Ehime University Graduate School of Medicine
                [ 7 ] Division of Diagnostic Pathology Ehime University Hospital
                [ 8 ] Department of Integrative Life Sciences Graduate School of Life Sciences, Tohoku University
                Author notes
                [*] [* ] Correspondence Masashi Maekawa and Shigeki Higashiyama, Division of Cell Growth and Tumor Regulation, Proteo‐Science Center, Ehime University Shitsukawa, Toon, 791‐0295 Ehime, Japan. Email: masashim@ 123456m.ehime-u.ac.jp (M.M.); shigeki@ 123456m.ehime-u.ac.jp (S.H.)

                [†]

                Tanigawa and Maekawa have equally contributed to this work.

                Author information
                http://orcid.org/0000-0002-9574-1906
                Article
                JCP28346
                10.1002/jcp.28346
                6617759
                30784076
                5046f65d-145a-484f-8191-49d2159cb062
                © 2019 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 26 November 2018
                : 31 January 2019
                : 01 February 2019
                Page count
                Figures: 5, Tables: 2, Pages: 15, Words: 9795
                Funding
                Funded by: YOKOYAMA Foundation for Clinical Pharmacology
                Award ID: Research Grant 2017 (YRY‐1703) to MM
                Funded by: JSPS
                Award ID: KAKENHI/JP18K16317 to KT
                Award ID: KAKENHI/JP16H046980 to SH
                Award ID: KAKENHI/JP18K15244 to MM
                Categories
                Original Research Article
                Original Research Articles
                Custom metadata
                2.0
                jcp28346
                October 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:10.07.2019

                Anatomy & Physiology
                angiogenesis,colorectal cancer,endothelial cells,integrin β1,sorting nexin 9
                Anatomy & Physiology
                angiogenesis, colorectal cancer, endothelial cells, integrin β1, sorting nexin 9

                Comments

                Comment on this article